OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine ...

Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and SGR-4174, its SOS1 inhibitor, will be presented at the American ...

Our SAFEbody masking capability enables the best therapeutic index among all CTLA-4 programs, showing the potential to unlock therapeutic value with a target previously limited by safety concerns.” Dr ...

Servier will lead the development activities and the worldwide commercialization of BDTX-4933 across multiple indications. Currently, in Phase 1 development, BDTX-4933 is designed to target RAS ...

And when chatbots get stressed out, they are less likely to be useful in therapeutic settings with people. The bot’s anxiety levels can be brought down, however, with the same mindfulness ...

The landscape of cancer treatment has been transformed by immune checkpoint inhibitors; however, the failure to benefit a large number of patients with cancer has underlined the need to identify ...

As such, they can occasionally face significant barriers under Health Canada's existing regulations. These innovative products are known as advanced therapeutic products. They can be either drugs or ...

US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase I trial of S-1117, a treatment for autoimmune diseases. The double ...

Levitin’s latest book, "I Heard There Was A Secret Chord: Music as Medicine," explains how our brains process music and lays out the evidence for the therapeutic benefits music can have.

TIOBE Index for March 2025: Top 10 Most Popular Programming Languages and Legacy Resurgence Your email has been sent The March TIOBE Index has revealed an interesting trend: legacy programming ...

On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...